Furthermore, SFN orchestrates a multi-pronged assault on cancer cells by promoting the acetylation of non-histone proteins such as p53, and synergistically activating critical pathways including cell cycle arrest, apoptosis, and sensitization to other therapeutic agents like TRAIL, which is particularly promising for targeting therapy-resistant cases (66). The gene discussed is SFN; the disease is cancer.